Cargando…
Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis
In the early SARS-CoV-2 (COVID-19) pandemic, four major vaccines were approved despite limited efficacy and safety data through short regulatory review periods. Thus, it is necessary to assess the benefit-risk (BR) profiles of the COVID-19 vaccines. We conducted a quantitative BR assessment for four...
Autores principales: | Son, Kyung-Hwa, Kwon, Sun-Hong, Na, Hye-Jung, Baek, Youngsuk, Kim, Inok, Lee, Eui-Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785565/ https://www.ncbi.nlm.nih.gov/pubmed/36560439 http://dx.doi.org/10.3390/vaccines10122029 |
Ejemplares similares
-
A benefit–risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients
por: Byun, Ji-Hye, et al.
Publicado: (2016) -
A comparison of various aggregation functions in multi-criteria
decision analysis for drug benefit–risk assessment
por: Menzies, Tom, et al.
Publicado: (2022) -
Multi-Criteria Decision Analysis for Benefit-Risk Analysis by National Regulatory Authorities
por: Chisholm, Orin, et al.
Publicado: (2022) -
Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases
por: Schey, Carina, et al.
Publicado: (2020) -
Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs
por: Iskrov, Georgi, et al.
Publicado: (2016)